NCT01136226View on ClinicalTrials.gov

Evaluate Recovery of Testosterone for Patients Using Eligard

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Prostate Cancer
Interventions
DRUG

Eligard (TM)

Eligard (TM) 22.5 mg administered at baseline and Month 3

Sponsors

Collaborators (1)

Sanofi-Synthelabo
All Listed Sponsors
collaborator

Sanofi-Synthelabo

INDUSTRY

lead

Chesapeake Urology Research Associates

OTHER